FDA did not raise concerns regarding the clinical efficacy or safety data of OLC, and no additional data was requested Unicycive Therapeutics, Inc. (NASDAQ:UNCY) We remain confident in the efficacy ...
-- Labeling discussions currently underway; latest communication received by the Company from FDA on June 29 regarding carton and container label -- -- FDA did not raise concerns regarding the ...
We are issuing Buy rating on Unicycive Therapeutics stock after the recent second CRL with a scenario-weighted DCF sum-of-the-parts, SOTP price target of $10 (75% upside). FDA issued a second CRL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results